Earnings

Plasma Revenue Lifts Haemonetics Fiscal 2Q Profit

 

BRAINTREE, Mass. (AP) — Haemonetics Corp. said Monday its profit grew 22 percent in the fiscal second quarter due to improved revenue from products used in collecting blood plasma.

The blood collection and processing systems maker said its profit rose to $18.1 million, or 69 cents per share. That compares with $14.8 million, or 57 cents per share, a year ago. Revenue increased 8 percent, to $157.1 million from $145.9 million.

Analysts were expecting 65 cents per share and $157.8 million in revenue, according to a Thomson Reuters survey.

In the three months ended Sept. 26, Haemonetics said plasma disposables revenue climbed 19 percent to $59 million, and platelet disposables revenue rose 3 percent to $37 million. Red cell disposables revenue fell 2 percent to $11 million and software solutions revenue rose 29 percent to $9 million.

For the full year, the company maintained its profit forecast of $2.75 to $2.85 per share, with revenue growth of 8 to 11 percent. Haemonetics reported $598 million in revenue in fiscal 2009, so the outlook implies $645.8 million to $663.8 million in revenue.

Analysts expect a profit of $2.81 per share and revenue of $654 million in fiscal 2010.

In afternoon trading, Haemonetics shares gained $2.49, or 4.8 percent, to $53.99.

>To order reprints of this article, click here: Reprints

Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

TheStreet Premium Services

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
Dow Jones S&P 500 NASDAQ 10-Year Note
12,393.45 1,310.33 2,827.34 15.81
Oil *
101.78
DOWN
26.41
DOWN
2.99
DOWN
10.02
DOWN
0.44
10 Yr
1.58%
SPDR Gold
151.62
-0.21%
-0.23%
-0.35%
-2.71%
Data delayed 20 minutes

Top Stories and Tools

Articles From

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet